PTC Therapeutics VP sells 1,638 shares under 10b5-1 plan
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
PTC Therapeutics VP Mark Boulding sold 1,638 shares of the company's stock for Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context